Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
Robin Cherian, Bharatendu Chandra, Moon Ley Tung, Alain Vuylsteke. COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness. Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020

Member's Comments

No comment yet.

Related content which might interest you: COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Revising our approach to conducting therapeutic clinical research in COPD Source: Eur Respir J, 51 (2) 1702712; 10.1183/13993003.02712-2017 Year: 2018 A pragmatic guide to choosing biologic therapies in severe asthma Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021 Year: 2021 COPD – will new insights into molecular pathology define new therapies? Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 HOPE-BAL: A novel tool to expand the methodological capabilities in pulmonary research Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Current and emerging approaches to the genetic diagnosis of chILDs Source: International Congress 2014 – Interstitial lung disease (ILD) in children Year: 2014 Halotherapy and Covid-19: an oppinion for a possible future prevention approach Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021 Bronchiectasis: state-of-the-art diagnostic and therapeutic approaches Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 From the bedside: upcoming new clinical strategies Source: International Congress 2016 – Scientific Year in Review 2016 Year: 2016 The paradoxes of asthma management: time for a new approach? Source: Eur Respir J, 50 (3) 1701103; 10.1183/13993003.01103-2017 Year: 2017 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 The concept of control in COPD: a new proposal for optimising therapy Source: Eur Respir J 2014; 44: 1072-1075 Year: 2014 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 Clinical implications of the new concepts regarding COPD pathophysiology Source: Annual Congress 2008 - New insights into COPD pathophysiology Year: 2008 Is poor asthma self-management due to failure to recognise symptoms or failure to act? Novel insights from mining large-scale clinical observational study Source: International Congress 2019 – M-health/e-health II Year: 2019 From staging to therapy: implications of the new staging system with a focus on multi-modal treatment options Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 The future: treating specific endotypes Source: International Congress 2015 – PG2 Asthma and COPD Year: 2015